Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis
Autoři:
Seon-Sook Han aff001; Su Jin Lee aff002; Jae-Joon Yim aff003; Jin Hwa Song aff003; Eun Hye Lee aff004; Young Ae Kang aff004
Působiště autorů:
Department of Internal Medicine, Kangwon National University Hospital, School of Medicine, Kangwon National University, Chuncheon, Republic of Korea
aff001; Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea
aff002; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Daehak-ro, Jongno-gu, Seoul, Republic of Korea
aff003; Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea
aff004
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0222810
Souhrn
Objective
Healthcare workers (HCWs) are one of the target groups for systematic testing and treatment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed this study to describe the testing of HCWs for LTBI and analyse the acceptance and completion of treatment of LTBI.
Methods
This retrospective cohort study was conducted in four university-affiliated hospitals between January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay (IGRA) during LTBI screening were analysed. We assessed the acceptance and completion of LTBI treatment.
Results
Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evaluation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6%) were offered treatment for LTBI. The proportion of acceptance for treatment was 64.5% (195 of 302 HCWs). The treatment course was completed by 143 of 195 HCWs (73.3%). Three months of isoniazid and rifampin (3HR) was used in 137 HCWs (70.3%) and 4 months of rifampin (4R) in 58 (29.7%). 72 HCWs (36.9%) experienced at least one adverse drug events, but there was no different characteristics between completer and non-completer.
Conclusion
The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspective regarding obstacles to treatment of LTBI needs to be explored to increase compliance to LTBI treatment.
Klíčová slova:
Medicine and health sciences – Infectious diseases – Bacterial diseases – Tuberculosis – Tropical diseases – Health care – Health care providers – Medical doctors – Physicians – Diagnostic medicine – Tuberculosis diagnosis and management – Pharmacology – Adverse reactions – Pharmaceutics – Drug therapy – People and places – Population groupings – Professions – Medical personnel – Biology and life sciences – Organisms – Bacteria – Actinobacteria – Mycobacterium tuberculosis – Social sciences – Economics – Labor economics – Employment
Zdroje
1. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271–86. Epub 2012/12/19. doi: 10.1146/annurev-publhealth-031912-114431 23244049.
2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet. 2015;385(9979):1799–801. Epub 2015/03/31. doi: 10.1016/S0140-6736(15)60570-0 25814376.
3. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F. Tuberculosis among health care workers. Emerg Infect Dis. 2011;17(3):488–94. Epub 2011/03/12. doi: 10.3201/eid1703.100947 21392441; PubMed Central PMCID: PMC3298382.
4. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2018.
5. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–70. Epub 2006/09/27. doi: 10.1001/archinte.166.17.1863 17000943.
6. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6):1712–7. Epub 2006/12/15. doi: 10.1378/chest.130.6.1712 17166986.
7. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292–7. Epub 2009/08/07. doi: 10.1016/j.ijid.2009.05.007 19656705.
8. Horsburgh CR Jr., Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401–9. Epub 2009/10/02. doi: 10.1378/chest.09-0394 19793865.
9. Lee SW, Jang YS, Park CM, Kang HY, Koh WJ, Yim JJ, et al. The role of chest CT scanning in TB outbreak investigation. Chest. 2010;137(5):1057–64. Epub 2009/11/03. doi: 10.1378/chest.09-1513 19880906.
10. Cho KS. Tuberculosis control in the Republic of Korea. Epidemiol Health. 2018;40:e2018036. Epub 2018/08/08. doi: 10.4178/epih.e2018036 30081621; PubMed Central PMCID: PMC6335497.
11. Cho KS PW, Jeong HR, Kim MJ, Park SJ, Park AY. Prevalence of latent tuberculosis infection at congregated settings in the Republic of Korea, 2017. Public Health Wkly Rep (Korean) 2018;11:7.
12. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018;379(5):440–53. Epub 2018/08/02. doi: 10.1056/NEJMoa1714283 30067931.
13. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555–64. Epub 1982/01/01. 6754120; PubMed Central PMCID: PMC2536088.
14. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2009.
15. Jensen PA, Lambert LA, Iademarco MF, Ridzon R, Cdc. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141. Epub 2005/12/31. 16382216.
16. Mullie GA, Schwartzman K, Zwerling A, N'Diaye DS. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Med. 2017;15(1):104. Epub 2017/05/19. doi: 10.1186/s12916-017-0865-x 28514962; PubMed Central PMCID: PMC5436424.
17. Png ME, Yoong J, Ong CWM, Fisher D, Bagdasarian N. A screening strategy for latent tuberculosis in healthcare workers: Cost-effectiveness and budget impact of universal versus targeted screening. Infect Control Hosp Epidemiol. 2019:1–9. Epub 2019/02/23. doi: 10.1017/ice.2018.334 30786941.
18. Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center. Clin Infect Dis. 2017;65(12):2105–11. Epub 2017/10/12. doi: 10.1093/cid/cix725 29020308; PubMed Central PMCID: PMC5850550.
19. Kim HW, Kim JS. Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy. Tuberc Respir Dis (Seoul). 2018;81(1):6–12. Epub 2018/01/15. doi: 10.4046/trd.2017.0052 29332319; PubMed Central PMCID: PMC5771748.
20. Lee EH, Kim SJ, Ha EJ, Park ES, Choi JY, Leem AY, et al. Treatment of latent tuberculous infection among health care workers at a tertiary hospital in Korea. Int J Tuberc Lung Dis. 2018;22(11):1336–43. Epub 2018/10/26. doi: 10.5588/ijtld.18.0280 30355414.
21. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. Epub 2011/12/14. doi: 10.1056/NEJMoa1104875 22150035.
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- Proč jsou nemocnice nepřítelem spánku? A jak to změnit?
- Dlouhodobá ketodieta může poškozovat naše orgány
- „Jednohubky“ z klinického výzkumu – 2024/42
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- MUDr. Jana Horáková: Remise již dosahujeme u více než 80 % pacientů s myastenií